To analyze the effects of conventional polychemotherapy of acute myeloblastic leukemia (AML) patients on the prooxidants/antioxidants balance in plasma total antioxidant status (TAS) and a single plasma antioxidant -uric acid (UA) were measured. Lipid peroxidation was assessed by malonedialdehyde (MDA) content. Total serum iron was monitored as a potential source of nontransferrin-bound iron with a role in initiation of oxidative burst. A group of patients in the acute phase of AML (group A) and a group of patients in complete remission of AML (group B) were studied. A strong correlation between UA values and TAS (r = 0.8 for group A, r = 0.9 for group B) was revealed in the course of the treatment. Strong negative correlation (r = −0.9) between TAS and MDA was shown for both groups. Total iron significantly increased in the course of chemotherapy. We have established that polychemotherapy leads to the consumption of antioxidants and increased lipid peroxidation in AML patients. An appropriate supplementation with antioxidants at the end of the polychemotherapy treatment could be considered.
Introduction
The pathophysiology of cancer is associated with the increased generation of reactive oxygen species (ROS) and lipid peroxidation processes [1] [2] [3] . Chemotherapy is a routine method for the treatment of neoplastic diseases. Chemotherapy and radiation therapy are also associated with increased formation of ROS and depletion of plasma and cellular antioxidants [4, 5] . Increased plasma lipid hydroperoxides and thiobarbituric acid-reactive substances (TBARS) suggest oxidative stress in patients receiving chemotherapy [6] [7] [8] . There is evidence that a variety of anticancer drugs exert their cytotoxic activity by a freeradical-mediated mechanism [9, 10] . These drugs include anthracyclines [11, 12] , as well as etoposide [13] [14] [15] , 1-β-D-arabinofuranosylcytosine (ara-C) [16] and others. Treatment of acute leukemia, such as acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL), includes combinations of cytotoxic drugs, which could overwhelm the cell antioxidative resistance mechanisms and lead to a condition known as oxidative stress.
Evidence that toxic ROS were generated in cultured AML blast cells following Ara C treatment were presented by flowcytometric detection of ROS and by measurement of reduced glutathione content [17] . The degree of lipid peroxidation in patients of ALL and AML was studied as a marker of disease activity [18] . Impaired plasma antioxidative defense and an increased nontransferrin-bound iron (NTBI) during high dose chemotherapy and radiochemotherapy preceding bone marrow transplantation have been detected in AML patients [5] . It still remains unclear whether these observations occur when lower doses of polychemotherapy are administered and how do they develop in the time course.
The aim of this study was to investigate whether leukemia patients who underwent conventional polychemotherapy showed signs of oxidative stress and antioxidant depletion in the course of their treatment. The assessment of their serum antioxidant status and levels of lipid peroxidation could be crucial for the evolution of future therapeutic strategies. To analyze the effects of polychemotherapy on the prooxidants/antioxidants balance in plasma we measured total antioxidant status (TAS) and a single plasma antioxidant -uric acid, known to account for a considerable percentage of the overall antioxidant protection of plasma [19] . Serum iron levels were also monitored as a potential source of NTBI with a role in initiation of oxidative burst. Plasma levels of TBARS assessed by malonedialdehyde (MDA) content were measured as products of lipid peroxidation. A group of patients in the acute phase of AML and a group of patients in complete remission of AML were studied.
Materials and methods

Patients and controls
The study was performed between October 2001 and March 2003 in the Clinics of Hematology of University Hospital "St. Marina" Varna and the Department of Pharmacology and Biochemistry of the University of Medicine Varna. Oxidative stress and antioxidant capacity were investigated in a selected group of 19 patients (7 males, 12 females), hospitalized for treatment of AML, who gave their informed written consent to participation in the study, according to the principles of the Declaration of Helsinki. Patients were divided into two groups -a group of 12 patients (mean age 55,9 ± 9,9 years: 5 males and 7 females) were in the acute phase of the disease (group A) and a group of 7 patients (mean age 44,1 ± 16,3 years: 2 males and 5 females) were in complete remission of AML (group B). The morphological variant of leukemia was defined according to the FAB classification and patients' WHO performance status was estimated prior to the treatment ( Table 1) . Patients with high number of blast cells (over 30 × 10 9 /l) were excluded from the study due to expected chemotherapy-induced hyperuricemia as a result of tumor-lysis syndrome. All patients were treated with cytostatics according the protocols AML-10 and AML 7+3 applied in the Clinics of Hematology ( Table 2 ). None of them had laboratory or clinical evidence of renal failure. Patients with clinical or biochemical features of acute infection or inflammation were not enrolled in the study. Severe liver disease was excluded by means of clinical, biochemical and ultrasound examinations. No patient was affected by wasting syndrome (body mass index was between 20.9 and 28.0). Routine laboratory tests were carried out before the treatment: hemoglobin, full blood count, differential blood count, glucose, creatinin, total protein, AsAT, AlAT, GGT, alcaline phosphatase, and LDH activities. 
*Data are presented as medians
A group of 14 healthy volunteers (mean age 41.4 ± 12.7 years: 6 males and 8 females) was used as a control. Exclusion criteria for control subjects were presence of neurological or endocrinological diseases, diabetus mellitus, arterial hypertension, prior myocardial infarction or stroke, infections, other inflammatory or malignant diseases.
Neither patients, nor controls were given vitamin-mineral supplements. 
Blood sample collection and handling
Blood samples from patients were collected one day before administration of cytotoxic drugs and on the 1 st , 4 th , 7 th day of chemotherapy, and on the day when leukocyte count was lower than 1 × 10 9 /l (nadir). Since pre-analytic conditions may affect the assays, blood collection and handling were carried out under strictly standardized conditions. Venous blood was taken in serum and plasma vacuettes from Greiner Bio-one. To obtain serum blood was incubated for 20 min at 37
• C and after that centrifuged at 3000× g for 10 min. Plasma was obtained by centrifugation of blood (2000× g for 20 min). Serum and plasma were immediately transferred into coded plastic tubes, snap frozen and stored at -80
• C until analysis.
The assays were carried out after thawing the frozen aliquots for 5 min in a water-bath at 37
• C and mixing them gently.
Full blood count, total antioxidant status, uric acid, malondialdehyde, serum iron, and total and direct bilirubin content were determined for all patients before and in the course of the chemotherapy cycle.
Serum antioxidant status and lipid peroxidation assay
Serum oxidative stress was measured as described by Porter at al. [20] by the content of TBARS used as a marker for lipid peroxidation in serum. MDA, an end product of lipid peroxidation, was determined spectrophotometrically at 532 nm on Specol 11 and was presented as nmol/ml serum. 1,1,3,3-tetramethoxypropan from Aldrich-Chemie (Steinheim, Germany) was used as a standard.
Serum iron content was determined by the standard colorimetric test with ferrozine (SPINREACT, S. A.). The measurements were performed on automated multichannel analyzer COBAS MIRA.
Total antioxidant status was estimated using the Total antioxidant status kit (RAN-DOX Laboratories Ltd., Ardmore, UK), based on the method of Miller et al. [21] . This method measures the overall capacity of human serum antioxidants to quench ABTS rad-ical cation (ABTS ·+ ), expressed as mmol TROLOX equivalents per liter. The measurements were performed using an automated multichannel analyzer ABBOTT SPECTRUM EPX. The levels of uric acid (UA) in serum were determined as compounds of the antioxidant defense. Uric acid content was evaluated using enzymatic colorimetric test (URICASE -PAP) based on Trinder-Reaction. The measurements were performed on automated multichannel analyzer COBAS MIRA.
Statistical analysis
Paired t test was used to compare the baseline values (0 day) with the values on days 1, 4, 7, and on nadir. p values of < 0.05 were regarded as significant. The independent t test was used to compare groups of patients. Correlation was quantified using Spearman rank correlation coefficient test. All statistical analyses were performed using SPSS 11.1.0 statistical software.
Results
Antioxidant status
TAS levels of healthy volunteers were measured to be in the reference range of the method: 1.30 -1.77 mmol/l serum. Before starting chemotherapy serum TAS values of group A patients were in the reference range too -1.41 mmol/l, while the average TAS values of patients from group B were below the lower range values of the controls -1.27 mmol/l (p < 0.001) ( Table 3 ). In both groups an increase of serum TAS values at the 1 st and 4 th days of chemotherapy was registered: 8 % increase for group A and 24 % for group B at the 1 st day and 11 % and 20 % at day 4, for groups A and B, respectively. The increase was statistically significant (p < 0.05) only in the case of group B. Slightly lower TAS values were measured at the 7 th day of chemotherapy and on the nadir, not statistically significant (p > 0.05). The variations in TAS values were similar for both groups. Uric acid as being one of the main blood antioxidant components was measured in serum throughout the therapy regimens. Uric acid values were within the normal range (women 148-357 μmol/l; men 200-416 μmol/l) -279 μmol/l for group A and 320 μmol/l for group B prior administration of cytostatics. The concentration of uric acid increased soon after administration of cytostatics for both groups (on the 1 st day) and kept increasing up to the 4 th day for group A patients (Table 3) . A statistically significant reduction of serum uric acid concentrations in the course of chemotherapy (p < 0.05) was later measured on the 7 th day and on the nadir for both groups. Comparison between the two groups did not show significant variation in serum uric acid contents. Data analysis revealed a strong correlation between uric acid as an antioxidant and serum TAS measured ( Fig. 1 ) -group A: r = 0.8, p < 0.05; group B: r = 0.9, p < 0.05. Serum levels of bilirubin, considered as a potential antioxidant in blood [22] , did not show variations before and during chemotherapy of all AML patients (data not shown).
Oxidative stress
The concentration of plasma MDA was estimated to be within the range of 2.31 to 5.70 nmol/ml for the control group. Pretreatment MDA levels were determined to be 6.36 nmol/ml and significantly higher (p < 0.05 vs controls) for group A and within the norm for group B (Table 3 ). In the course of chemotherapy a slight decrease in MDA values was measured on the 1 st and 4 th days followed by an increase, significant (p < 0.05) on the 7 th day for group B and on the nadir for both groups. Comparison between the groups revealed statistically significant differences (p < 0.05) only on the day preceding chemotherapy. Correlation analysis (Fig. 2) showed strong negative correlation between TAS values and MDA content for both groups (r = -0.9). Total serum iron significantly increased during chemotherapy (Table 3) for both groups on day 4 and day 7 (p < 0.05) and on the nadir for group B (p < 0.05). Extremely high (about 40 μmol/l) and exceeding the reference values (women 6.6 -26.0 μmol/l, men 10.7 -28.6 μmol/l) was serum iron content on the 4 th and on 7 th days of treatment of patients from group B, which results in significant differences (p < 0.05) in the serum iron value variations between the two groups. High serum iron still did not negatively correlate with TAS values (r = 0.6 in group A and r = -0.3 in group B, Fig. 3 ) and with UA values (data not shown).
Discussion
As free radicals have been implicated in the pathogenesis of leukemias, we studied the degree of lipid peroxidation as a marker of developing oxidative stress in AML patients. Pretreatment values of plasma lipid peroxidation product MDA were in the normal range in patients in complete remission of AML. MDA in untreated patients with acute AML was above the normal range, indicating the occurrence of oxidative stress in agreement with previously reported data demonstrating lipid peroxidation in acute leukemias [18] . This oxidative stress deepened further as a result of the administration of cytostatics as shown by the additional increase in MDA levels in treated patients over the time period studied. An increase in lipid peroxidation and free radical generation in patients with other types of cancer [4] or after high dose chemotherapy [5] have been previously reported. Elevated total serum iron measured in our study in the course of conventional chemotherapy of both groups with AML could be a potential source of NTBI and thus an initiator of free radical generation through Fenton reaction. On the nadir when leukocyte count was lower than 1.10 9 /l serum iron measured was still exceeding the normal range. This could rather be due to the poor utilization of iron by the bone marrow or to its ROS-facilitated release from the iron store pools, than to an abnormal erythrocyte lysis, however not detected by an increase in bilirubin levels during the chemotherapy.
Blood total antioxidant status is the result of the interaction of many different compounds and systemic metabolic interactions. And while TAS of the cells is mainly attributable to the enzyme systems, that of plasma is mostly accounted for by low molecular weight antioxidants, such as uric acid and antioxidants of dietary origin, and also by thiol groups of proteins. Despite the evidences for increased lipid peroxidation and oxidative stress, pretreatment TAS and UA content measured were within the normal range. An elevated content and not a consumption of total serum antioxidants and uric acid were detected already on day 1 after the start of chemotherapy course. The strong correlation between uric acid as an antioxidant and serum TAS measured after administration of cytostatics could rather be a result from the release of intracellular antioxidants during the cytostatics-induced lysis of blast cells, than a result of an upregulation of antioxidants induced by disease-related oxidative stress, as suggested earlier [8, 15] . Monitoring of the oxidative stress markers provided evidence for an impaired balance between antioxidants and prooxidants in blood, confirmed by the strong negative correlation between serum TAS and MDA levels. Chemotherapy -induced free radical generation and oxidative stress probably lead to the consumption of important antioxidants such as uric acid, followed by a decrease in serum TAS. Radical production causes peroxidation of lipids, which results in the detection of increased levels of MDA. This could be the crucial moment for an antioxidant supplementation therapy as ROS may cause or contribute to certain side effects that are common to many anticancer drugs. Supplementation of antioxidants might affect clinical outcome and improve quality of patients' life.
Serum TAS and iron content correlated poorly, which does not allow accepting total iron content as a routine laboratory indicator for predicting oxidative stress. Rather an additional estimation of NTBI would be more demonstrative.
Monitoring of MDA, uric acid and TAS levels are indicative and may be used as markers for impaired prooxidants/antioxidants balance in myeloblastic leukemias.
This study specified the moment when the oxidative stress in AML patients extended and antioxidant abilities of the organism were reduced. Our data will contribute to form a consent opinion for administration of antioxidants at the time when they would not any more interfere with the basic anticancer drugs activity.
